

# Julie Refardt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3851523/publications.pdf>

Version: 2024-02-01

45  
papers

1,146  
citations

623734

14  
h-index

414414

32  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1200  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Sodium Levels on Functional Outcomes in Patients With Stroke – A Swiss Stroke Registry Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e672-e680.	3.6	4
2	Effect of hyponatremia normalization on osteoblast function in patients with SIAD. <i>European Journal of Endocrinology</i> , 2022, 186, 1-8.	3.7	10
3	Molecular Imaging in neuroendocrine neoplasias. <i>Presse Medicale</i> , 2022, 51, 104115.	1.9	2
4	Approach to the Patient: –Utility of the Copeptin Assay– <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1727-1738.	3.6	22
5	Molecular Imaging of Neuroendocrine Neoplasms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2662-e2670.	3.6	9
6	Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases. <i>Endocrine-Related Cancer</i> , 2022, 29, 241-250.	3.1	3
7	Prognostic value of dysnatremia for survival in neuroendocrine neoplasm patients. <i>European Journal of Endocrinology</i> , 2022, , .	3.7	1
8	The effect of glucose dynamics on plasma copeptin levels upon glucagon, arginine, and macimorelin stimulation in healthy adults. <i>Pituitary</i> , 2022, 25, 636-644.	2.9	4
9	Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 581-594.	5.7	29
10	Diagnosis and management of diabetes insipidus for the internist: an update. <i>Journal of Internal Medicine</i> , 2021, 290, 73-87.	6.0	43
11	Incidence of hyperkalemia during hypertonic saline test for the diagnosis of diabetes insipidus. <i>Endocrine Connections</i> , 2021, 10, 401-409.	1.9	2
12	Oxytocin Levels in Response to Pituitary Provocation Tests in Healthy Volunteers. <i>Journal of the Endocrine Society</i> , 2021, 5, A631-A631.	0.2	0
13	Validity of Different Copeptin Assays in the Differential Diagnosis of the Polyuria-Polydipsia Syndrome. <i>Journal of the Endocrine Society</i> , 2021, 5, A637-A637.	0.2	0
14	Validity of different copeptin assays in the differential diagnosis of the polyuria-polydipsia syndrome. <i>Scientific Reports</i> , 2021, 11, 10104.	3.3	19
15	Can treatment response to SGLT2-inhibitors in syndrome of inappropriate antidiuresis be predicted by copeptin, natriuretic peptides and inflammatory markers?. <i>Biomarkers</i> , 2021, 26, 647-655.	1.9	3
16	Hyponatremia Intervention Trial (HIT): Study Protocol of a Randomized, Controlled, Parallel-Group Trial With Blinded Outcome Assessment. <i>Frontiers in Medicine</i> , 2021, 8, 729545.	2.6	6
17	A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	7
18	Oxytocin levels in response to pituitary provocation tests in healthy volunteers. <i>European Journal of Endocrinology</i> , 2021, 185, 355-364.	3.7	5

#	ARTICLE	IF	CITATIONS
19	New Directions in Imaging Neuroendocrine Neoplasms. <i>Current Oncology Reports</i> , 2021, 23, 143.	4.0	5
20	Diabetes Insipidus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 517-531.	3.2	42
21	Low arginine vasopressin levels in patients with diabetes insipidus are not associated with anaemia. <i>Clinical Endocrinology</i> , 2020, 93, 456-465.	2.4	4
22	Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers. <i>Endocrine</i> , 2020, 70, 292-298.	2.3	9
23	Diagnosis and differential diagnosis of diabetes insipidus: Update. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101398.	4.7	31
24	Effects of alcohol consumption on copeptin levels and sodium-water homeostasis. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F702-F709.	2.7	7
25	A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 615-624.	6.1	51
26	Effect of Arginine on the Hypothalamicâ€“Pituitaryâ€“Adrenal Axis in Individuals With and Without Vasopressin Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2327-e2336.	3.6	4
27	Copeptin is not useful as a marker of malignant disease in the syndrome of inappropriate antidiuresis. <i>Endocrine Connections</i> , 2020, 9, 20-27.	1.9	6
28	Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging. <i>Endocrine-Related Cancer</i> , 2020, 27, 615-624.	3.1	15
29	Copeptin-based diagnosis of diabetes insipidus. <i>Swiss Medical Weekly</i> , 2020, 150, w20237.	1.6	7
30	Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. <i>Lancet, The</i> , 2019, 394, 587-595.	13.7	97
31	Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis. <i>Clinical Endocrinology</i> , 2019, 91, 22-32.	2.4	66
32	Effects of Glucagon-Like Peptide-1 Receptor Agonists on Hypothalamic-Pituitary-Adrenal Axis in Healthy Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 202-208.	3.6	5
33	Cosyntropin testing does not predict response to glucocorticoids in communityâ€“acquired pneumonia in a randomized controlled trial. <i>Clinical Endocrinology</i> , 2019, 91, 374-382.	2.4	4
34	The challenges of sodium measurements: indirect versus direct ion-selective method. <i>European Journal of Endocrinology</i> , 2019, 181, 193-199.	3.7	13
35	Hypercalcemic crisis in third trimester: evaluating the optimal treatment strategy. <i>Gynecological Endocrinology</i> , 2018, 34, 833-836.	1.7	7
36	Copeptin levels and commonly used laboratory parameters in hospitalised patients with severe hypernatraemia - the â€œCo-MED studyâ€“. <i>Critical Care</i> , 2018, 22, 33.	5.8	19

#	ARTICLE	IF	CITATIONS
37	Copeptin in the Diagnosis of Diabetes Insipidus. <i>New England Journal of Medicine</i> , 2018, 379, 1784-1786.	27.0	7
38	Impact of chronic hyponatremia on neurocognitive and neuromuscular function. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13022.	3.4	27
39	A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. <i>New England Journal of Medicine</i> , 2018, 379, 428-439.	27.0	180
40	Diabetes insipidus in pregnancy: how to advice the patient?. <i>Minerva Endocrinology</i> , 2018, 43, 458-464.	1.1	7
41	FGF-21 levels in polyuria-polydipsia syndrome. <i>Endocrine Connections</i> , 2018, 7, 1501-1506.	1.9	0
42	Artificial Syndrome of Inappropriate Antidiuresis Model as Potential Use for Diagnostic and Therapeutic Strategies. <i>Hormone and Metabolic Research</i> , 2017, 49, 673-679.	1.5	2
43	Effects of Inadequate Amino Acid Mixture Intake on Nutrient Supply of Adult Patients with Phenylketonuria. <i>Annals of Nutrition and Metabolism</i> , 2017, 71, 129-135.	1.9	14
44	Empagliflozin Increases Short-Term Urinary Volume Output in Artificially Induced Syndrome of Inappropriate Antidiuresis. <i>International Journal of Endocrinology</i> , 2017, 2017, 1-8.	1.5	22
45	Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2015, 385, 1511-1518.	13.7	326